What are CYP17 inhibitor drugs?

CYP17 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CYP17). 0 are currently marketed, with 8 more in clinical development.

CYP17 inhibitor

0 marketed 1 in Phase 3 3 in Phase 2 4 in Phase 1

This page covers all CYP17 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CYP17.

Targets

CYP17

Phase 3 pipeline (1)

SoluMatrix™ Abiraterone Acetate · GU Research Network, LLC · Oncology
Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, in the body.

Phase 2 pipeline (3)

Abiraterone acetate standard dose · Assistance Publique - Hôpitaux de Paris · Oncology
Inhibits CYP17, an enzyme involved in the production of androgens.
Abiraterone acetate tablets · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
CYP17 inhibitor
Abiraterone - Usual · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Oncology
Abiraterone is an androgen biosynthesis inhibitor that blocks the production of testosterone in the body.

Phase 1 pipeline (4)

Abiraterone: Treatment A · Janssen Research & Development, LLC · Oncology
Inhibits CYP17, a key enzyme in the biosynthesis of androgens.
Abiraterone: Treatment C · Janssen Research & Development, LLC · Oncology
CYP17 inhibitor
Abiraterone acetate suspension Formulation 1 · Cougar Biotechnology, Inc. · Oncology
Androgen receptor inhibitor
Abiraterone acetate MTD · Cougar Biotechnology, Inc. · Oncology
Androgen receptor inhibitor